Displaying drugs 10276 - 10300 of 12439 in total
Aganirsen
Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).
Investigational
Matched Description: … at Risk of Developing NVG). ... Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients …
ORG-34517
ORG-34517 is currently under investigation by Organon for the treatment of depression. It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Investigational
Matched Description: … etc, in which the activity of metabolites corticosterone and cortisol is high. ... ORG-34517 is currently under investigation by Organon for the treatment of depression. ... It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma …
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Description: … activity against the coronavirus family of viruses. ... new virions, resulting in the accumulation of inactivating mutations. ... A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of …
IN01
The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria . These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence . Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies . Of note,...
Investigational
Matched Description: … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of ... Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing ... life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine. …
Cyamemazine
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Description: … class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. ... Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine ... actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
XL784
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because ... Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers ... of its important role in blood vessel formation and cell proliferation. …
ARC183
ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and specificity. The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life,...
Investigational
Matched Description: … The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short ... ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that ... , giving it the potential to be an ideal agent for medical procedures that require rapid resolution of …
CRx-401
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of …
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Matched Description: … 7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes ... the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. …
Camrelizumab
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Investigational
Matched Description: … ED-SCLC After Failure of First Line Standard Therapy). ... is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of …
RSV-604
RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Investigational
Matched Description: … Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.). ... is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of …
Foralumab
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Investigational
Matched Description: … Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab …
Tilsotolimod
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Investigational
Matched Description: … With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)). ... Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination …
DLO6002
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Investigational
Matched Description: … DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of …
Romilkimab
Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).
Investigational
Matched Description: … the Treatment of Idiopathic Pulmonary Fibrosis). ... Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in …
Sibofimloc
Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).
Investigational
Matched Description: … of Postoperative Crohn's Disease (CD)). ... Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence …
Ianalumab
Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Investigational
Matched Description: … Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 …
DTX-101
DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.
Investigational
Matched Description: … It was previously investigated for the treatment of hemophilia B; however, the clinical development of ... DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector …
LX201
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Matched Description: … to the eye over the course of one year. ... LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally ... LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) …
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … that promotes growth and production of blood platelets. ... SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor ... used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of …
Melperone
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It has been well established in the treatment of confusion, anxiety, restlessness (particularly in...
Investigational
Matched Description: … Melperone has been used for a span of greater than 30 years in the European Union [L1316]. ... Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related ... Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. …
Lumicitabine
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
Matched Description: … Food on the Pharmacokinetics of the 2 New Concept Formulations). ... is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of ... Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of …
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Displaying drugs 10276 - 10300 of 12439 in total